| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
3 companies
Ernest Mario last filed a Form 4 in June 2024, as Director at HYPD. The filings on record cover 3 companies. Ernest Mario's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 382,706 shares of HYPD. Net of sales, the HYPD filings show accumulation of 208,402 shares.
Ernest Mario has 65 Form 4 filings on record from January 2015 to June 2024, across 3 companies: Director at Soleno Therapeutics (SLNO), 2015–2024; Director at Hyperion Defi (HYPD), 2018–2021; Director at Tonix Pharmaceuticals (TNXP), 2016–2018.
The 96 reported transactions were 33 stock awards, 23 open-market purchases, 18 option or other derivative awards and 7 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 14 purchases worth about $1.8M and 2 sales worth about $156K.
The largest open-market purchase was 90,000 shares of HYPD at an average $10.00 on January 29, 2018, about $900K.
The largest open-market sale was 36,967 shares of TNXP at an average $3.51 on December 21, 2017, about $130K.
Shares as reported in the last Form 4 for each company; the most recent is from June 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2022 | SLNO Soleno Therapeutics Inc | Director | Buy | 1,860,000 | $0.00 | - | -200.0% | -11.8% | -36.0% | |
| Mar 24, 2020 | HYPD Hyperion Defi, Inc. | Director | Buy | 82,431 | $2.27 | $187,118.37 | +33.7% | - | - | |
| Jul 11, 2019 | HYPD Hyperion Defi, Inc. | Director | Buy | 35,971 | $2.78 | $99,999.38 | +15.2% | - | - | |
| Jun 25, 2018 | TNXP Tonix Pharmaceuticals Holding Corp. | Director | Buy | 16,500 | $4.48 | $73,920.00 | +49.3% | - | - | |
| Jan 29, 2018 | HYPD Hyperion Defi, Inc. | Director | Buy | 90,000 | $10.00 | $900,000.00 | +61.3% | - | - | |
| Dec 21, 2017 | TNXP Tonix Pharmaceuticals Holding Corp. | Director | Sell | 36,967 | $3.51 | $129,814.31 | -61.1% | - | - | |
| Jun 30, 2017 | TNXP Tonix Pharmaceuticals Holding Corp. | Director | Sell | 6,105 | $4.28 | $26,117.19 | -50.9% | - | - | |
| Nov 23, 2016 | TNXP Tonix Pharmaceuticals Holding Corp. | Director | Buy | 120,000 | $0.41 | $48,600.00 | New | - | - | |
| Oct 31, 2016 | TNXP Tonix Pharmaceuticals Holding Corp. | Director | Buy | 100,000 | $0.00 | - | +18.8% | - | - | |
| Sep 13, 2016 | TNXP Tonix Pharmaceuticals Holding Corp. | Director | Buy | 100,000 | $0.79 | $79,180.00 | +23.2% | - | - |